Sangart, Inc. is a biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents.

Hemospan® has been administered in almost 1,000 subjects to date including orthopedic surgery patients in two European multi-center Phase III clinical trials completed in the first half of 2008.

Sangart’s products are based upon extensive research into the factors that govern oxygen delivery by cell-free hemoglobin.